Market Research Report
NORTH AMERICA DRUG DISCOVERY MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||609209|
|Published||Content info||91 Pages
Delivery time: 1-2 business days
|NORTH AMERICA DRUG DISCOVERY MARKET FORECAST 2018-2026|
|Published: March 2, 2018||Content info: 91 Pages||
The revenue generated by the North American drug discovery market is expected to escalate over the forecast period of 2018-2026, growing at a CAGR of 9.50%.
Growing lifestyle oriented diseases, increase in healthcare spending and technological advancement in cardiology are chiefly driving the demand for North American drug discovery market. More than 90 million Americans carry a diagnosis of CVD. However, US has the world's finest hospitals and clinics for cardiology surgeries and other heart-related procedures, which is majorly responsible for the country's dominant share in this market. The Canadian market is also catching up. The country spent approximately $242 billion on health care in 2017, a rise of almost 4% from the previous year.
Established players in this market include Bayer Ag, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Llc, Pfizer Inc, Boehringer Ingelheim, Eli Lily, AstraZeneca Plc and Merck & Co. Inc.